Lancaster Cancer Center Participates in Nationwide Clinical Trial

December 2, 2016 @ 8:04 pm – December 13, 2016 @ 8:34 pm

Partners with the Chronic Lymphocytic Leukemia Registry to Support Research Efforts

Lancaster Cancer Center (LCC) recently participated in a clinical trial to aid in the research of chronic lymphocytic leukemia. LCC was one of 199 centers nationwide who contributed to the trial. Four patients under the care of Lancaster Cancer Center agreed to be part of the research.

The data from the study will be presented at the American Society of Hematology’s annual meeting in San Diego, CA, December 3-6, 2016. The study is titled “Early Progression of Disease (< 2 Years) Is a Negative Predictor of Survival in Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): An Analysis from the Connect® CLL Registry.”

Lancaster Cancer Center participates in 6-8 clinical trials per year and is currently involved in six active trials focusing on multiple myeloma, myelodysplastic syndrome and acute myeloid leukemia, chronic lymphocytic leukemia, cancer of unknown primary and non-small cell lung cancer with five of the six trials open to enrollment of LCC patients.

According to research, it is estimated that from 2010 to 2014, preventable deaths from cancer decreased by 25 percent. Clinical trials allow the medical community to observe current practices, try new treatments and improve the overall care of patients.

In this particular study, the objective was to create a way to identify high-risk patients and observe if the patients could have progression less than or equal to two years after initiation. The Chronic Lymphocytic Leukemia Registry is an observational study that collects data about how patients were treated for their disease across the country.

Information from clinical trials allows the study team to compare practices and create a standard measure of treatment. The information can also highlight potential common problems or side effects and quality of life. Patients have a research team monitoring their overall status and contribute to better treatment of future patients through their participation.

“Lancaster Cancer Center has been participating in clinical trials for 30 years and we are proud of the lives we have saved through our efforts,” said Robert Orzechowski, COO. “While our daily mission at LCC is the treatment, care and recovery of our patients, we are also dedicated to the practice of cancer prevention. These trials allow us to be part of the larger fight against cancer.”

For more information, please contact the Lancaster Cancer Center at 717-291-1313.